Diana Acosta

Diana Acosta

Auto-generated profile, based on publicly available information

Diana Acosta

Department of Biochemistry, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYun Yang
Yun Yang
Victor Tapias MolinaVictor Tapias Molina
Victor Tapias Molina
DADiana Acosta
Diana Acosta
HXHui Xu
Hui Xu
HCHuanlian Chen
Huanlian Chen
GGGary Gibson
Gary Gibson
Abnormalities in brain glucose metabolism and accumulation of abnormal protein deposits called plaques and tangles are neuropathological hallmarks of Alzheimer’s disease (AD), but their relationship to disease pathogenesis and to each other remains unclear. Here we show that succinylation, a metabolism-associated post-translational protein modification (PTM), provides a potential link between abnormal metabolism and AD pathology. We quantified the lysine succinylomes and proteomes from brains of individuals with AD, and healthy controls. In AD, succinylation of multiple mitochondrial proteins declined, and succinylation of small number of cytosolic proteins increased. The largest increases occurred at critical sites of amyloid precursor protein (APP) and microtubule-associated tau. We show that in vitro, succinylation of APP disrupted its normal proteolytic processing thereby promoting Aβ accumulation and plaque formation and that succinylation of tau promoted its aggregation to tangles and impaired microtubule assembly. In transgenic mouse models of AD, elevated succinylation associated with soluble and insoluble APP derivatives and tau. These findings indicate that a metabolism-linked PTM may be associated with AD.

22 July 2020
Verified
Book Chapter
Open access
PDF file
DADiana Acosta
Diana Acosta
TDTapojyoti Das
Tapojyoti Das
DEDavid Eliezer
David Eliezer
The microtubule-associated protein tau has been extensively studied as a culprit in Alzheimer’s disease and other neurodegenerative diseases known as tauopathies. Challenges in structurally defining tau protein emerge from its disordered nature, which makes it difficult to crystallize, and hinder efforts to interpret tau protein’s true function. The complexity of intrinsically disordered proteins (IDPs) necessitates a multifaceted approach to study their interactions including multiple spectroscopic methods that can report on local protein environment and structure at individual residue positions. We and others have shown that in addition to binding to microtubules, tau binds to lipid membranes. Tau-membrane interactions may be relevant both to normal tau function and to tau aggregation and pathology. Here we describe the use of fluorescence spectroscopy as a probe of protein-membrane interactions to determine whether there is an interaction, which residues participate, and the extent/nature of the interface between the protein and the membrane. We provide a protocol for how the membrane interactions of tau protein, as an example, can be probed by fluorescence spectroscopy, including details of how the samples should be prepared and guidelines on how to interpret the results.